Kv1.1 (KCNA1) Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Kv1.1 (KCNA1) Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>EAC1FDB2-KCNA1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Kv1.1 (KCNA1)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=EAC1FDB2-KCNA1" target="_blank">Search UniProt</a></td>
</tr>
</table>
Kv1.1 is the protein encoded by [KCNA1](/genes/kcna1), a voltage-gated potassium channel alpha subunit in the Kv1 (Shaker-related) family.[@jan2012][@gutman2005] Kv1.1 participates in action-potential repolarization, spike-frequency control, and axonal excitability tuning across central and peripheral circuits. In disease biology, Kv1.1 dysfunction is strongly linked to episodic ataxia and related hyperexcitability syndromes, and it remains relevant to neurodegeneration as an excitability and network-stability node.[@browne1994][@glasscock2010]
Protein Architecture and Assembly
Kv1.1 has the canonical six-transmembrane topology (S1-S6) with a pore loop between S5 and S6. Functional channels form tetramers and often include heteromeric Kv1 partners and cytosolic accessory subunits that modify kinetics and trafficking.[@jan2012][@gutman2005]
Key structural features:
...Kv1.1 (KCNA1) Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Kv1.1 (KCNA1) Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>EAC1FDB2-KCNA1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Kv1.1 (KCNA1)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=EAC1FDB2-KCNA1" target="_blank">Search UniProt</a></td>
</tr>
</table>
Kv1.1 is the protein encoded by [KCNA1](/genes/kcna1), a voltage-gated potassium channel alpha subunit in the Kv1 (Shaker-related) family.[@jan2012][@gutman2005] Kv1.1 participates in action-potential repolarization, spike-frequency control, and axonal excitability tuning across central and peripheral circuits. In disease biology, Kv1.1 dysfunction is strongly linked to episodic ataxia and related hyperexcitability syndromes, and it remains relevant to neurodegeneration as an excitability and network-stability node.[@browne1994][@glasscock2010]
Protein Architecture and Assembly
Kv1.1 has the canonical six-transmembrane topology (S1-S6) with a pore loop between S5 and S6. Functional channels form tetramers and often include heteromeric Kv1 partners and cytosolic accessory subunits that modify kinetics and trafficking.[@jan2012][@gutman2005]
Key structural features:
- Voltage-sensing S4 helix
- Pore/selectivity region defining K<sup>+</sup> conductance
- Cytosolic regions supporting assembly and regulatory interactions
- Axonal targeting determinants for compartment-specific function
This architecture enables fast voltage-dependent gating suited for millisecond-scale control of neuronal firing.
Physiologic Function
Action Potential Repolarization
Kv1.1 contributes outward potassium current during and after depolarization, preventing runaway repetitive firing and preserving signal precision.[@jan2012][@vacher2008]
Axonal Conduction and Synaptic Timing
At axonal and juxtaparanodal regions, Kv1-family channels shape conduction reliability and transmitter release dynamics. This timing control is critical in cerebellar and corticothalamic circuits where small excitability shifts can produce large systems-level symptoms.[@browne1994][@glasscock2010]
Excitability Reserve in Stress States
When neuronal metabolism is impaired or inflammatory signaling rises, potassium-channel reserve becomes even more important. Kv1.1 dysfunction can lower resilience thresholds and increase susceptibility to network instability, seizures, and maladaptive plasticity.[@glasscock2010][@chandy2017]
Disease-Relevant Evidence
Episodic Ataxia Type 1 and Neuromyotonia
Pathogenic KCNA1/Kv1.1 variants are a well-established cause of episodic ataxia type 1 (EA1), often with myokymia and peripheral nerve hyperexcitability. Disease phenotypes arise primarily from altered gating or reduced functional current, producing hyperexcitable motor circuits.[@browne1994][@zuberi1999]
Epilepsy and Network Hyperexcitability
Kv1.1 channel dysfunction can contribute to seizure susceptibility through impaired repolarization reserve and abnormal synchronization. This supports the broader concept that potassium-channel instability can accelerate neural system fragility in mixed pathologies.[@glasscock2010][@chandy2017]
Neurodegeneration-Relevant Framing
Kv1.1 is not a primary monogenic cause of AD/PD, but it remains mechanistically relevant as a circuit-stability regulator linked to:
- [Ion channel dysfunction](/mechanisms/ion-channel-dysfunction)mechanisms/ion-channel-dysfunction-neurodegeneration)
- [Calcium homeostasis disruption](/mechanisms/calcium-homeostasis-disruption)
- [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Synaptic dysfunction](/mechanisms/synaptic-dysfunction)
This modifier framing is useful in precision models where excitability burden interacts with proteostasis and inflammatory load.[@glasscock2010][@chandy2017][@surmeier2017]
Therapeutic Considerations
Clinical management in KCNA1-associated channelopathy has historically used anti-excitability agents (for example carbamazepine or acetazolamide in selected phenotypes), but response heterogeneity is common.[@zuberi1999] For neurodegeneration translation, key priorities are biomarker-defined subgrouping and safer channel-specific modulation strategies.
Important translational questions:
Which patient subsets show dominant excitability-driven progression?
Can Kv1.1-oriented modulation improve functional outcomes without cognitive cost?
How should excitability therapies be combined with disease-modifying programs?Research Priorities
- Map human cell-type-specific Kv1.1 changes across AD/PD/ALS progression
- Build genotype-phenotype models for KCNA1 variants and circuit-level biomarkers
- Test Kv1.1-informed combination designs with mitochondrial or anti-inflammatory therapies
- Harmonize electrophysiology endpoints for multicenter translational studies
See Also
- [KCNA1 Gene](/genes/kcna1)
- [Ion channel dysfunction](/mechanisms/ion-channel-dysfunction)mechanisms/ion-channel-dysfunction-neurodegeneration)
- [Synaptic dysfunction](/mechanisms/synaptic-dysfunction)
- [Calcium homeostasis disruption](/mechanisms/calcium-homeostasis-disruption)
- [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
External Links
- [UniProt: Kv1.1 / KCNA1](https://www.uniprot.org/uniprot/P09488)
- [NCBI Gene: KCNA1](https://www.ncbi.nlm.nih.gov/gene/3736)
References
[Jan LY, Jan YN, Voltage-gated potassium channels and the diversity of electrical signalling (2012)](https://pubmed.ncbi.nlm.nih.gov/1840554/)
[Gutman GA, Chandy KG, Grissmer S, et al, International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels (2005)](https://pubmed.ncbi.nlm.nih.gov/16382104/)
[Browne DL, Gancher ST, Nutt JG, et al, Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1 (1994)](https://pubmed.ncbi.nlm.nih.gov/7842010/)
[Glasscock E, Yoo JW, Chen TT, Klassen TL, Noebels JL, Kv1.1 potassium channel deficiency reveals brain-driven cardiac dysfunction as a candidate mechanism for sudden unexplained death in epilepsy (2010)](https://pubmed.ncbi.nlm.nih.gov/20375136/)
[Vacher H, Mohapatra DP, Trimmer JS, Localization and targeting of voltage-dependent ion channels in mammalian central neurons (2008)](https://pubmed.ncbi.nlm.nih.gov/21383131/)
[Chandy KG, Norton RS, Peptide blockers of Kv1 channels in autoimmune and neuroinflammatory disease (2017)](https://pubmed.ncbi.nlm.nih.gov/33719549/)
[Zuberi SM, Eunson LH, Spauschus A, et al, A novel mutation in the human voltage-gated potassium channel gene KCNA1 associates with episodic ataxia type 1 and sometimes partial epilepsy (1999)](https://pubmed.ncbi.nlm.nih.gov/9703420/)
[Surmeier DJ, Obeso JA, Halliday GM, Selective neuronal vulnerability in Parkinson disease (2017)](https://pubmed.ncbi.nlm.nih.gov/25442937/)